DEA Argues Synthetic HHC Was Already Federally Controlled

DEA told the Fourth Circuit that its new HHC drug code is only a tracking change because synthetically produced HHC was already treated as Schedule I, and argued that Bluestar Operations lacks standing to challenge the rule. Oklahoma hemp manufacturers should treat synthesis method and federal controlled-substance exposure as distinct compliance risks even when products originate from hemp-derived CBD.